Tozinameran

Abstract

Internal jugular vein thrombosis: case report A 38-year-old man developed internal jugular vein thrombosis after receiving vaccination with Tozinameran for COVID-19 infection*. The patient, who had a history of opioid abuse on buprenorphine/naloxone [Suboxone], received the first dose of COVID-19 vaccination with Tozinameran [BNT162b2 mRNA vaccine; dose received and route not stated] on 18 April 2021. Two days later, the patient developed chest pain, dyspnoea, left neck swelling and dry cough with odynophagia. Ultrasonography (US) showed a clot. Carotid ultrasound revealed non-compressible internal jugular vein and CT chest showed left innominate vein thrombus. Laboratory investigations showed increased PT, PTT, leucocytosis, thrombophilia, increased LDH and D-Dimer. Patient’s intranasal PCR was negative for COVID-19 and other respiratory viruses. During admission, patient’s malignancy work up was negative. Based on various findings, the patient was diagnosed with internal jugular vein thrombosis related to the vaccination [outcome not stated].